A61P 25/16
Anti-parkinson drugs
Official title: Anti-Parkinson drugs
A61P25/16 (Anti-parkinson drugs) appears on 12,852 US grants and 20,465 published applications in this corpus.
Search patents in A61P- Granted patents
- 12,852
- Published applications
- 20,465
- Assignees
- 4,755
- Inventors
- 28,487
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1977 | 1 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 1 | 0 |
| 1981 | 1 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 1 | 0 |
| 1991 | 3 | 0 |
| 1992 | 4 | 0 |
| 1993 | 3 | 0 |
| 1994 | 8 | 0 |
| 1995 | 16 | 0 |
| 1996 | 21 | 0 |
| 1997 | 45 | 0 |
| 1998 | 70 | 0 |
| 1999 | 89 | 0 |
| 2000 | 126 | 0 |
| 2001 | 196 | 66 |
| 2002 | 243 | 408 |
| 2003 | 275 | 674 |
| 2004 | 251 | 873 |
| 2005 | 257 | 905 |
| 2006 | 393 | 914 |
| 2007 | 412 | 942 |
| 2008 | 438 | 1096 |
| 2009 | 533 | 1199 |
| 2010 | 672 | 1525 |
| 2011 | 679 | 1328 |
| 2012 | 784 | 1200 |
| 2013 | 856 | 914 |
| 2014 | 859 | 983 |
| 2015 | 808 | 963 |
| 2016 | 675 | 873 |
| 2017 | 709 | 822 |
| 2018 | 598 | 750 |
| 2019 | 586 | 814 |
| 2020 | 520 | 634 |
| 2021 | 447 | 582 |
| 2022 | 324 | 489 |
| 2023 | 287 | 468 |
| 2024 | 257 | 429 |
| 2025 | 272 | 363 |
| 2026 | 130 | 251 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin6 Oct 2026US 12,751,960 B2Compass Pathfinder Limited
- Methods of reducing neuroinflammation6 Oct 2026US 12,751,994 B2ImmunityBio, Inc.
- Compound and composition for preventing or treating neuroinflammatory brain diseases comprising same as active ingredient6 Oct 2026US 12,753,186 B2Korea Institute of Ocean Science & Technology
- Methods and compositions for treating neurodegenerative diseases22 Sep 2026US 12,740,995 B2Augusta University Research Institute, Inc.
- Methods of differentiating neural cells and related compositions and methods of use15 Sep 2026US 12,734,196 B2Aspen Neuroscience, Inc.
- Methods of determining glucose hypometabolism-induced energy crisis and treatments thereof8 Oct 2026US 2026/0306018 A1Senovia Biosciences LLC
- Subcutaneously administered treatments for advanced parkinson’s disease8 Oct 2026US 2026/0306517 A1AbbVie Inc.
- Intra-striatal co-transplantation of autologous treg and mda cells in parkinson's disease cell therapy8 Oct 2026US 2026/0306543 A1The McLean Hospital Corporation
- Modified adeno-associated virus vector and use thereof in treating neurological diseases8 Oct 2026US 2026/0306673 A1Genecombio Ltd.
- Oxysterols and methods of use thereof8 Oct 2026US 2026/0308197 A1Sage Therapeutics, Inc.
Most cited
By later US patents
- Modular infusion device and method1,554US 6,749,587 B2Insulet Corporation · 2004
- Biocompatible devices with foam scaffolds984US 6,054,142 ACyto Therapeutics, Inc. · 2000
- Solid carriers for improved delivery of active ingredients in pharmaceutical compositions930US 6,248,363 B1Lipocine Inc. · 2001
- Solid carriers for improved delivery of active ingredients in pharmaceutical compositions684US 6,923,988 B2Lipocine Inc. · 2005
- Primate embryonic stem cells641US 5,843,780 AWisconsin Alumni Research Foundation · 1998